Pipeline

One regenerative platform. Multiple chronic wound indications.

Komava is developing a modular regenerative wound care platform designed to address the distinct biological barriers associated with difficult-to-heal wounds.

Lead indication: Neuroischemic diabetic foot ulcers
Current stage: Lead optimisation
Pipeline: 3 targeted chronic wound indications

Development pipeline

Building a pipeline from a common regenerative platform.

Our initial development focuses on diabetic foot ulcers, with pressure ulcers and venous leg ulcers providing additional opportunities for the platform.

Komava’s product candidates combine a common bacterial cellulose-based wound care platform with acellular regenerative payloads selected according to the biological needs of each targeted indication.

Diabetic foot ulcers are prioritised as the lead indication for clinical development, followed by pressure ulcers and venous leg ulcers.

Complete Current stage Ahead

1Discovery
2Lead optimisation
3Preclinical and CMC
4Clinical development

KOMA-DFU Neuroischemic Diabetic Foot Ulcers

Now

KOMA-PU Pressure Ulcers

Now

KOMA-VLU Venous Leg Ulcers

Now

Lead programme: KOMA-DFU.

Lead indication

Diabetic Foot Ulcers

DFU · KOMA-DFU

Diabetic Foot Ulcers

Lead indication

Diabetic foot ulcers are a serious complication of diabetes and remain a major cause of morbidity, hospitalisation and lower-limb amputation.

Komava has selected neuroischemic diabetic foot ulcers as its lead indication, where impaired perfusion, neuropathy and disrupted tissue repair create multiple biological barriers to healing.

Selection rationale. The indication was prioritised based on unmet medical need, market opportunity and the potential for a regenerative approach to address key limitations of current wound management.

18.6 million estimated new diabetic foot ulcers each year, worldwide 6.3% estimated prevalence among adults living with diabetes worldwide Int J Environ Res Public Health. 2025 Mar 21;22(4):463.

Pipeline expansion

Extending the platform across chronic wound indications.

The modular design of the Komava platform provides the opportunity to develop indication-specific regenerative therapies while retaining a common underlying wound care technology.

VLU · KOMA-VLU

Venous Leg Ulcers

Venous leg ulcers are chronic wounds associated with venous hypertension, persistent inflammation and microcirculatory dysfunction.

Their high prevalence, particularly in ageing populations, represents an important potential expansion opportunity for the Komava platform.

1 to 3% estimated lifetime prevalence in the general population in Western countries up to 5% estimated prevalence among people over 65, at the upper end Journal of Tissue Viability, Volume 34, Issue 1, February 2025.

PU · KOMA-PU

Pressure Ulcers

Pressure ulcers result from prolonged mechanical loading and tissue ischaemia and remain a significant challenge in hospital, long-term care and home-care settings.

The combination of ischaemia, inflammation and impaired tissue regeneration makes pressure ulcers another potential application for Komava’s regenerative platform.

2.47 million estimated new pressure ulcer cases globally in 2021 Front Public Health. 2025 Feb 26;13. Wound Repair Regen. 2025 Jul 11;33(4):e70064.

Beyond wound care

Building a dermatology therapeutics pipeline.

Komava’s pipeline is designed to leverage a common technology platform across multiple wound and dermatological indications.

By combining a scalable biomaterial platform with indication-specific therapeutic payloads, Komava aims to build a differentiated portfolio of locally delivered therapies.

The science in full Partner with Komava

Let’s advance regenerative wound care.

We welcome discussions with biotechnology and pharmaceutical companies, scientific collaborators, development organisations and investors interested in advancing the Komava platform.

Contact Komava Partnering enquiries